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Abstract
Rationale Experimental data informs that not only do the dose
and time duration of dependent drugs affect the severity of
withdrawal episodes. Previous withdrawal experiences may
intensify this process, which is referred as sensitization to
withdrawal signs. Adenosine and dopamine (DA) receptors
may be involved in this sensitization.
Objectives Rats were continuously and sporadically treated
with increasing doses of morphine for 8 days. In rats, sporad-
ically treated with morphine, morphine administration was
modified by adding three morphine-free periods. Adenosine
agonists were given during each of the morphine-free periods
(six injections in total). On the 9th day, morphine was injected.
One hour later, naloxone was administered to induce mor-
phine withdrawal signs. Then, the animals were placed into
cylinders and the number of jumpings was recorded. Next, the
rats were decapitated and brain and brain structures (striatum,
hippocampus, and prefrontal cortex) were dissected for neu-
rochemical, molecular, and immunohistochemical experi-
ments within DAergic pathways.
Results We demonstrated that previous experiences of opioid
withdrawal intensified subsequent withdrawal signs.
Adenosine ligands attenuated the sensitization to withdrawal
signs. In a neurochemical study, the release of DA and its
metabolites was impaired in all structures. Significant alter-
ations were also observed in mRNA and protein expression of
DA receptors.
Conclusions Results demonstrate that intermittent treatment
with morphine induces alterations in the DAergic system
which may be responsible for sensitization to morphine with-
drawal signs. Although adenosine ligands attenuate this type
of sensitization, they are not able to fully restore the physio-
logical brain status.
Keywords Morphinewithdrawal signs . Naloxone .
Dependence .Morphinewithdrawal signs . Dopamine
receptor expression
Introduction
Chronic treatment with morphine and other opioids produces
addiction, while cessation of morphine administration induces
withdrawal symptoms (Chartoff et al. 2006; Georges et al.
1999; Kaplan and Coyle 1998). In most experimental proce-
dures, morphine withdrawal signs are induced by
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administration of increasing morphine doses for several con-
secutive days (Balter and Dykstra 2012; Hao et al. 2011;
Trang et al. 2003). However, in cases of addicted patients,
chronic treatment with different abusing substances is often
interspersed with drug-free periods, e.g., the periods of sleep
or impossibility of taking the drug. Moreover, according to
experimental data, not only do the dose and time duration of
the treatment with addictive drugs affect the severity of with-
drawal episode but previous withdrawal experiences may also
intensify this process, what is referred to as sensitization to
withdrawal signs (Mizutani et al. 2005; Ward and Stephens
1998). For example, certain sensitization to withdrawal signs
was observed after repeated ethanol withdrawal (increase in
the number of seizure episodes) (Becker et al. 1997; Veatch
and Becker 2002). Similarly, some increase in the intensity of
withdrawal symptoms was observed after repeated morphine
withdrawals in guinea pigs (Mizutani et al. 2005) and after
repeated heroine withdrawals in rats (Schulteis et al. 1997).
Subsequent studies with diazepam, another addictive com-
pound, also confirmed the sensitization development to with-
drawal signs (Listos et al. 2008a; Ward and Stephens 1998).
However, the exact mechanisms, underlying this sensitization
process, are still rather poorly identified.
It is well known that the dopamine (DA) and DAergic
mesocortical limbic system plays an important role in mor-
phine effects, with increased DA levels in the nucleus accum-
bens after acute morphine doses (Di Chiara 2000). Other brain
structures, such as the ventral tegmental area, the ventral stri-
atum, the amygdala nuclei, and the prefrontal cortex nuclei,
are also involved in the activity of opioids (Koob et al. 2004).
A cessation of chronic treatment with morphine induces op-
posite effects, such as decreased DA neurotransmission in the
nucleus accumbens, which underlies anhedonia and dysphoria
during withdrawal period (Acquas et al. 1991; Koob et al.
1989). DA exerts its effects on five DA receptors, out of which
D1 and D2 receptors are most recognized and their role in the
addiction process is undisputed (Goodman 2008). However,
alterations in sensitization to morphine withdrawal signs, ob-
served in the DAergic system, have not been studied.
Adenosine, a potent inhibitory neuromodulator in the central
nervous system, acts via fourmost recognized adenosine receptor
subtypes: A1, A2A, A2B, and A3. A1 receptors are highly
expressed in different brain areas, such as the cortex, the cerebel-
lum, the hippocampus, and the dorsal horn of the spinal cord.
The distribution of A2A receptors is more limited, mainly in the
striato-pallidal GABAergic neurons and the olfactory bulb. In
other brain areas, their expression levels are much lower (Ferré
et al. 1997). It has repeatedly been shown that adenosine is in-
volved in the function of opioid system. It is known that extra-
cellular adenosine levels are increased after exposure to mor-
phine or to the other addictive drugs (Baldo et al. 1999), while
adenosine may be responsible for modification of addictive be-
haviors in animals. In experimental studies, the number of A1
adenosine receptors in the brain presented an increase, contrary
to decreased A2A receptors in the striatum, demonstrated in
morphine-dependent rats (Ahlijanian and Takemori 1986;
Kaplan et al. 1994). Furthermore, a close functional in vitro
interaction was also described between adenosine A1, A2A re-
ceptors andmorphinewithdrawal, see Capasso andGallo (2009).
Some involvement of adenosine ligands in the effect of chronic
opiate treatment was also demonstrated in behavioral experi-
ments. For example, adenosine agonists were able to reduce
opiate withdrawal signs inmice (Kaplan and Sears 1996), as well
as the development of morphine sensitization was inhibited by
adenosine receptor antagonists in a C57BL/6 mouse (Weisberg
and Kaplan 1999). We previously indicated that stimulation of
adenosine A2A receptors attenuated the development of hyper-
sensitivity to acute morphine doses during its withdrawal (Listos
et al. 2008b). We also showed that adenosine agonists signifi-
cantly attenuated morphine-induced sensitization to the locomo-
tor activity of mice, which was reflected by morphine seeking
behavior (Listos et al. 2011).
Taken together, all the above-mentioned data inspired us to
find out if sporadic morphine treatment, intermittent with repeat-
ed withdrawal periods, produced sensitization to naloxone-
induced withdrawal signs in rats. Out of various withdrawal
signs—jumpings in that case, as the most intense opioid with-
drawal signs, were selected for evaluation of that sensitization
type. Subsequently, the involvement of adenosine A1 and A2A
receptors in that sensitization mode was also studied.
Additionally, in order to elucidate the mechanisms of sensitiza-
tion tomorphine withdrawal signs, some series of neurochemical
and molecular experiments were also performed. In a neuro-
chemical study, using the high-performance liquid chromatogra-
phy with electrochemical detection (HPLC-ED) method, the
concentration levels of DA and its metabolites were assessed in
those brain structures which are strongly involved in addiction
process, such as the striatum, the hippocampus, and the prefrontal
cortex (Koob et al. 2004). The DA is catabolized by two ways:
via monoaminooxidase B (MAO-dependent oxidative pathway)
s y n t h e s i z e d i n t r a n e u r o n a l m e t a b o l i t e— 3 , 4 -
dihydroxyphenylacetic acid (DOPAC); via catechol-O-
methyltransferase (COMT-dependent o-methylation pathway)
synthesized the extraneuronal metabolite, 3-methoxytyramine
(3-MT). The final metabolite of DA is homovanillic acid
(HVA). In molecular experiments, the mRNA and protein ex-
pression of DA receptors D1 and D2 was investigated in the
same brain areas. Finally, immunohistochemical changes in the
expression of DA receptors were examined in the hippocampus.
The striatum is a brain structure which receives the inputs from
the basal ganglia, the cortex, the amygdala, and from other struc-
tures. It is strongly involved in various aspects of addiction status
(Delgado et al. 2003; Everitt and Robbins 2005; Tanaka et al.
2004). Striatum contains almost exclusively DA neurons.
Contrary to this, the hippocampus and cortex contain far fewer
DA projections; therefore, it is worth studying the alterations
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within all these structures. The distribution of D1 and D2 recep-
tors in these structures is also diversified. The hippocampus is a
structure, mainly involved in learning and remembering process-
es. Although it is not directly involved in the activity of abused
drugs, it was indicated that the hippocampus could mediate the
rewarding effects of morphine by D1 and D2 receptors in the
CA1 region (Esmaeili et al. 2012). The prefrontal cortex is an
area which is implicated in cognitive behaviors, personality ex-
pression, and inmoderating social behaviors. It sends the neurons
that innervate striatal and midbrain cell regions and it may there-
by be involved in the state of dependence. An identification of
molecular, neurochemical, and immunohistochemical changes
within those structures comprehensively explain the mecha-
nisms, underlying the behavioral differences between the rats,
chronically and sporadically treated with morphine, and those
which were treated with adenosine ligands. The presented exper-
iments may play a key role in further investigations on morphine




The experiments were carried out on male Wistar rats (180–
200 g). The animals were kept 8–10 per cage at a room tem-
perature of 22±1 °C on natural day-night cycles (12 h/12 h).
Standard food (Murigan pellets, Bacutil, Motycz) and tap wa-
ter were freely available. All the experiments were performed
between 8 a.m. and 3 p.m.
The study was performed according to the National
Institute of Health Guidelines for the Care and Use of
Laboratory Animals and the European Community Council
Directive for Care and Use of Laboratory Animals of 24
November (86/609/EEC) and were approved by Committee
on the Ethics of Animal Experiments of the Medical
University of Lublin (No 29/2012, No 1/2013).
Drugs in behavioral experiments
The following drugs were used:
& Morphine hydrochloride (Pharma-Cosmetic, Poland);
& Naloxone hydrochloride (Sigma, St. Louis, MO, USA)—
opioid receptor antagonist;
& N6-cyclopentyladenosine (CPA)—the selective adenosine
A1 receptor agonist;
& 2-p- (2 -Carboxye thy l ) phene thy lamino-5 ′ -N-
ethylcarboxamidoadenosine hydrochloride (CGS
21680)—the selective adenosine A2A receptor agonist.
All drugs were dissolved in 0.9 % saline and they were
given intraperitoneally (ip).
Morphine was used at increasing doses (from 10.0 to
50.0 mg/kg, ip). Naloxone hydrochloride was adminis-
tered at a dose of 2.0 mg/kg. Both adenosine ligands
were given at the dose of 0.1 mg/kg. All drugs were
administered in a volume of 10.0 ml/kg. Control ani-
mals received the same volume of saline at the respec-
tive time before the test.
Procedure of addiction and behavioral experiments
In order to obtain the state of dependence, the animals were
treated with increasing doses of morphine: 10.0, 15.0, 20.0,
25.0, 30.0, 35.0, 40.0, 50.0 mg/kg (for 8 days). Each dose of
morphine was given twice a day. We wanted to demonstrate that
sensitization to naloxone induced morphine withdrawal signs
developed in those rats and that the adenosinergic system was
involved in that process; thus, we divided the animals into the
following groups: (1) morphine group—consecutive morphine
administrations, according to the above scheme; (2) morphine-
sensitized group—morphine administration was modified by
three morphine-free periods. Thus, the administration of mor-
phine was divided into four 2-day periods (4×2), interspersed
with 36-h morphine-free periods. During each morphine-free
period, animals received two injections of saline; (3) CPA in
morphine-sensitized group—the animals received morphine, as
in the morphine-sensitized group, while during each morphine-
free period, the rats received two injections of CPA in 12-h in-
tervals; (4) CGS in sensitized group—the animals received mor-
phine as in the morphine sensitization group and, during each
morphine-free period, the rats received two injections of CGS
21680 in 12-h intervals; (5) saline—those animals received sa-
line in two patterns: for 9 consecutive days and, analogously to
themorphine-sensitized group, it means, for 12 consecutive days.
No behavioral differences were observed between these groups;
therefore, the status of saline group was assigned to them.
On the last day of the study (on the 9th day in the morphine
group and the saline group and on the 12th day in the
morphine-sensitized group and the CPA/CGS 21680 in
morphine-sensitized group), a subsequent dose of morphine
(50.0 mg/kg) was injected. One hour later, naloxone
(2.0 mg/kg) was administered to induce morphine withdrawal
signs in the rats. The animals were then separately placed in
glass cylinders and the number of jumpings was recorded for
the period of 30 min.
After the end of behavioral experiments, the rats were
killed by decapitation and their brains and brain structures
(the striatum, the hippocampus, and the prefrontal cortex)
were dissected.
The experimental protocol is graphically depicted in the
Scheme 1.
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Neurochemical analysis—ex vivo biochemical studies
After behavioral experiments, the rats were killed by decapitation
and their brain structures, including the striatum, the hippocam-
pus, the prefrontal cortex, and the cerebellum, were immediately
dissected and the obtained tissues were frozen on solid CO2
(−70 °C) and stored until biochemical assay. DA and its metab-
olites, DOPAC, 3-MT, and the final metabolite, HVA, were
assayed by means of HPLC-ED. A HP 1050 chromatograph of
Hewlett-Packard, Golden, CO, USA, was equipped with C18
columns. Tissue samples were weighed and homogenized in
ice-cold 0.1 M perchloroacetic acid, containing 0.05 mM of
ascorbic acid. After centrifugation (10,000×g, 5 min), the super-
natants were filtered through RC 58 0.2-im cellulose membranes
(Bioanalytical Systems, West Lafayette, IN, USA). The mobile
phase consisted of 0.05 M citrate-phosphate buffer, pH 3.5,
0.1 mM of EDTA, 1 mM of sodium octyl sulfonate, and 3.5 %
methanol. The flow rate was maintained at 1 ml/min. DA and its
metabolites were quantified by peak height comparisons with
standards run on the day of analysis.
Molecular analysis
The analysis of gene expression by real-time quantitative
reverse transcription PCR (RQ-PCR) in the striatum,
the hippocampus, and the prefrontal cortex
Total RNAwas extracted from50 to 100mg brain samples, using
an RNeasy Lipid Tissue Mini Kit (Qiagen). After determination
of the quantity and quality of isolated RNA, using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, USA),
cDNA was prepared from 1 μg of total cellular RNA in 20 μl
of reaction volume, using a First Strand cDNA synthesis kit and
oligo-dT primers (Fermentas). A quantitative assessment of
mRNA levels was performed by real-time RT-PCR on an ABI
7500Fast instrument with Power SYBRGreen PCRMaster Mix
reagent. The real-time conditions were as follows: 95 °C (15 s),
40 cycles at 95 °C (15 s), and 60 °C (1 min). According to
melting point analysis, only one PCR product was amplified
under those conditions. Each sample was analyzed in two tech-
nical replicates and the mean Ct values were used for further
analysis. The relative quantity of target, normalized to the endog-
enous control Gapdh gene and relative to a calibrator, is
expressed as 2-ΔΔCt (−fold difference), where Ct is the threshold
cycle, ΔCt = (Ct of target genes)− (Ct of endogenous control
gene, β-2 microglobulin), and ΔΔCt = (ΔCt of samples for the
target gene)− (ΔCt of calibrator for the target gene). The follow-
ing primer pairs were used:
D1R F: CGC GTA GAC TCT GAG ATT CTG AAT T,
D1R R: GAG TTA AGG AGC CAC CAC ATC AGT;
D2R F: TGA CAG TCC TGC CAA ACC AGA GAA,
D2R R: TGG GCA TGG TCT GGA TCT CAA AGA;
Gapdh F: ATG ACT CTA CCC ACG GCA AG, Gapdh
R: CTG GAA GAT GGT GAT GGG TT
The analysis of protein expression by the western blotting
method in the striatum, the hippocampus, and the prefrontal
cortex
A RIPA buffer (pH 7.4), containing 20 mM of Tris, 0.25 mM of
NaCl, 11 mM of EDTA, 0.5 % NP-40, 50 mM of sodium fluo-
ride, and protease, phosphatase inhibitors (Sigma, Poland) was
used for homogenization of the brain samples (Yant et al. 2003).
The total protein concentrations were determined, using the
Bradford Protein Assay (Sigma, Poland) and the homogenates
were subjected to SDS-polyacrylamide gel electrophoresis and
assessed for the expression of D1 and D2 receptors. Briefly, the
extracted proteins (20 μg/well) were separated on 12 % gel
(SDS-PAGE), using a Mini Protean Tetra Cell System (Bio-
Rad, Poland). The fractionated proteins were transferred onto a
0.2-μm PVDF membrane (Bio-Rad, Poland), next membranes
were blocked with 3 % bovine serum albumin (BSA) solution in
buffer for 1 h at room temperature. The brain protein expression
was identified, using antibody against D1-rabbit polyclonal
(SantaCruz Biotechnology, cat no sc-14001), D2-mouse mono-
clonal (SantaCruz Biotechnology, cat no sc-5303), GFAP-mouse
monoclonal (SantaCruz Biotechnology, cat no sc-33673), and
appropriate sAb bovine anti-rabbit/anti-mouse IgG HRP (Santa
Cruz Biotech, USA);
The membranes were processed with an ECL Advance
Western Blotting Detection Kit (Amersham Life Sciences,
UK) and, subsequently, bands were visualized, using the Gel
DOC-It Imaging system.
Immunohistochemical analysis of D1 and D2 receptors
in the hippocampus
The dissected brains were fixed in Carnoy liquid (1 h) and then
washed with absolute ethanol (three times within 3 h), absolute
ethanol with xylene (1:1) (twice within 1 h), and xylene (3 times
within 20min), and then, after 3-h saturation of tissues with liquid
paraffin, the samples were embedded in paraffin blocks. Using a
microtome (MICROM HM340E), 3–5 μm serial sections were
obtained and placed on silane histological slides (3-aminopropyl-
trietoxy-silane, Thermo Scientific, UK). The preparations were
deparaffinized in xylene and ethanol with decreasing concentra-
tion and then used for further histological staining. In order to
expose epitopes, the deparaffinized sections were twice boiled
in amicrowave oven (700W, 4 and 3min) in 10 nMcitrate buffer
(pH 6.0). Once cooled and washed with phosphate-buffered sa-
line (PBS), the preparations were incubated for 60 min at room
temperature with a primary antibody against D1, D2, like used for
western blotting analysis, in dilution 1:1000.
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In order to visualize the antigen-antibody complex for rab-
bit antibodies under light microscopy (Axioskop Zeiss,
Germany), we used the DAKO LSAB+System-HRP
(DakoCytomation, UK), based on the reaction avidin-biotin-
horseradish peroxidase with diaminobenzidine (DAB) as
chromogen. The result of that reaction was visualized, using
diaminobenzidine reaction (DAB, Sigma-Aldrich, Poland).
Statistical analysis
The behavioral results (see Fig. 1) and the neurochemical results
(see the Table 1) are presented as the mean values±S.E.M.
Those results were evaluated by the analysis of variance (one-
way ANOVA), using the Graph-Pad Prism Software package
(version 5.04). The post-hoc comparisons were carried out, using
the Tukey’s test. The total catabolic rate of DAwas assessed as
the ratio of the concentration of eachmetabolite (DOPAC, 3-MT,
HVA) to that of DA and was expressed as the catabolic rate
index: [metabolite] / [DA]×100. A probability value at p<0.05
was considered as statistically significant. Each group of the
animals consisted of 8–10 rats. The results of morphine group
and morphine-sensitized group were compared to saline group,
while the results of CPA/CGS 21680 in morphine-sensitized
group were compared to morphine-sensitized group.
The molecular results were analyzed, using the Statistica
10.0 Software package. The arithmetical mean value ±SD
was calculated for each studied parameter. The distribution of
results for individual variables was obtained by the Shapiro-
Wilk W test. As most of the real-time distributions deviated
from the normal distribution, non-parametric tests were used
for further analyses. In order to assess the differences between
the studied groups, the non-parametric Mann–Whitney U test
was used. The comparisons between groups were performed
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Scheme 1 Shows the procedure
of administration of morphine in
morphine group and morphine
and adenosine agonists (CPA and
CGS 21680) in morphine-
sensitized group
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Effects of continuous and sporadic morphine treatment
on the intensity of naloxone-induced morphine withdrawal
signs (jumpings). The role of adenosine A1 and A2A agonists
As the one-way analysis confirmed, significant changes were
observed in the intensity of withdrawal signs in those rats that
had chronically been treated with morphine and adenosine li-
gands (F4,71=21.18, p<0.0001). The number of jumpings in-
creased in the morphine group (p<0.05) when compared with
the saline group. Those episodes were significantly intensified in
the morphine-sensitized rats, in comparison with the saline rats
and the morphine group rats (p<0.001). Both CPA and CGS
21680 significantly reduced the number of withdrawal episodes
in the morphine-sensitized rats (p<0.001), see Fig. 1.
Neurochemical analysis
Influence of continuous and sporadic treatment
with morphine on DA and its metabolite concentration
in brain structures during withdrawal periods induced
by naloxone. The role of adenosine A1 and A2A agonists
In the striatum, the one-way ANOVA analysis revealed sig-
nificant changes in DA concentration (F5,61 = 4.835,
p = 0.001) and HVA/DA ratio (F5,31 = 3.523, p = 0.0145)
during the withdrawal period. The post-hoc test demonstrated
a significant decrease (p<0.01) in DA concentration in the
morphine group vs the saline group rats. Furthermore, no sig-
nificant changes were observed in the concentration levels of
all DA metabolites, but HVA/DA ratio was significantly ele-
vated in the morphine group (p<0.05). No significant changes
were observed after an acute dose of naloxone in the saline-
treated rats and in morphine-sensitized group. Neither CPA
nor CGS 21680 affected the concentration of DA or its me-
tabolites in the morphine-sensitized group rats, see Table 1.
Following ANOVA, significant changes were observed in
the concentrations of DA (F5,61= 7.085, p<0.0001) and of its
metabolites (DOPAC: F5,59 = 5.068, p<0.0007; 3-MT: F5,
63 = 25.38, p<0.0001; HVA: F5,62 = 7.727, p<0.0001; and
3-MT/DA ratio: F5,35=4.024, p=0.0065) in the hippocampus
of the studied rats. A post-hoc test indicated that an acute dose
of naloxone did not produce any changes in the hippocampal
DAergic pathways. The concentration of DA was markedly
reduced (p<0.05) in the morphine-sensitized group, but not in
the morphine group. The levels of two DA metabolites, such
as DOPAC and HVA, were also reduced (p<0.05) in that
group. Adenosine agonists did not affect the concentrations
of DA, DOPAC, or HVA. Conversely, compared to the saline
group, the concentration of 3-MT was markedly increased,
both in the morphine group (p<0.001) and in the morphine-
sensitized group rats (p<0.01) and 3-MT/DA ratio was also
elevated in these groups (p<0.001). Both adenosine ligands,
CPA and CGS 21680, significantly increased 3-MT levels
(p< 0.001 and p< 0.01, respectively) and 3-MT/DA ratio
(p<0.001) in comparison with the morphine-sensitized rats,
see Table 1.
In the prefrontal cortex, one-way ANOVA showed signif-
icant changes in the concentrations of DA (F5,55 = 6.807,
Fig. 1 Effects of continuous and sporadic treatment with increasing
doses of morphine on the intensity of naloxone-induced morphine
(mph) withdrawal signs (jumpings). The role of adenosine A1 and A2A
agonists. Rats were treated in two schemes: for 8 continuous days (mph
group) and for four 2-day periods (4 × 2) interspersed with morphine-free
period days (mph-sensitized group). Adenosine agonists (CPA—
0.1 mg/kg, ip and CGS 21680—0.1 mg/kg, ip) were administered
during the morphine-free periods. Naloxone (2.0 mg/kg, ip) was
administered for induction of morphine withdrawal signs. *p < 0.05,
***p< 0.001 vs saline group, ^^^p< 0.001 vs mph group, ###p< 0.001
vs mph-sensitized group (Tukey’s test)
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p = 0.0003) and its metabolites (DOPAC: F5,65 = 9.093,
p = 0.0001; 3-MT: F5,61 = 13.09, p < 0.0001; HVA: F5,
62 = 22.22, p < 0.0001; 3-MT/DA ratio: F5,32 = 5.538,
p=0.0012; and HVA/DA ratio: F5,33=7.689, p=0.0001) in
the morphine-treated animals. It was demonstrated in the
Tukey’s test that an acute dose of naloxone did not induce
any significant changes in comparison with the saline animals.
The Tukey’s test showed that DA level was increased both in
the morphine group (p<0.05) and in the morphine-sensitized
group (p < 0.001), in comparison with the saline group.
Significant increases (p<0.001) in all the metabolite concen-
trations (DOPAC, 3-MT, HVA) were observed in the
morphine-sensitized group, but not in the morphine group,
when compared to the saline group rats. The HVA/DA ratio
was reduced in the morphine group (p<0.05), and it was
elevated (p<0.05) in the morphine-sensitized group. In com-
parison with the morphine-sensitized group, 3-MT level
(p<0.01) and 3-MT/DA ratio (p<0.05) were significantly
elevated by CPA, see Table 1.
Molecular analysis
Influence of continuous and sporadic morphine treatment
on D1 receptor mRNA and protein expression in rat brain
structures during naloxone-induced withdrawal period.
The role of adenosine A1 and A2A agonists
Regarding the striatum, the expression of mRNA (p<0.01)
and protein (p<0.05) D1 receptor demonstrated a statisti-
cally significant decrease in the morphine group in com-
parison with the corresponding values in the saline group.
A significant down-regulation of mRNA (p<0.01) and
protein (p<0.01) of D1 receptor expression was also ob-
served in morphine-sensitized group in comparison with
saline group. No statistically significant changes were ob-
served in D1 receptor expression between the morphine
group and the morphine-sensitized group in that brain ar-
ea. Neither CPA nor CGS 21680 affected D1 receptor
expression in the morphine-sensitized group rats, see
Fig. 2.
In the hippocampus, mRNA and protein expression
of D1 receptor were significantly higher (both p< 0.01)
in the morphine-sensitized group, in comparison to the
saline group. No alterations were observed in the mor-
phine group rats vs the saline group rats. The mRNA
and protein expression of D1 receptors were significant-
ly up-regulated in the morphine-sensitized group vs the
morphine group (p < 0.01 and p < 0.05, respectively).
CGS 21680—an adenosine agonist—down-regulated
mRNA of D1 receptor (p < 0.05) and CPA down-
regulated protein expression of D1 receptors (p< 0.05)
in comparison with the morphine-sensitized rats, see
Fig. 2.
In the prefrontal cortex, increased D1 receptor mRNA
(p< 0.05) and protein (p< 0.05) expression levels were
observed in the morphine group vs the saline group,
while no significant alterations were found in the
morphine-sensitized group, compared to the saline
group. D1 receptor expression was significantly down-
regulated in the morphine-sensitized group vs morphine
group (p< 0.05). CPA up-regulated D1 receptor protein
expression (p< 0.05), in comparison with the morphine-
sensitized group, see Fig. 2.
An acute dose of naloxone did not induce any changes in
D1 receptor mRNA and protein expression levels in any of the
studied parts of the brain, see Fig. 2.
Influence of continuous and sporadic morphine treatment
on D2 receptor mRNA and protein expression in rat brain
structures during naloxone-induced withdrawal period.
The role of adenosine A1 and A2A agonists
In the striatum, the U-Mann test did not show any signif-
icant changes in D2 receptor mRNA or protein expression
levels in the morphine group vs the saline group; howev-
er, the mRNA and protein expression levels in the
morphine-sensitized group were significantly down-
regulated (p<0.01 and p<0.001) vs the saline group. D2
receptor expression in the morphine-sensitized group was
significantly down-regulated vs the morphine group
(p<0.05), see Fig. 3.
CPA significantly up-regulatedmRNA (p<0.001) and pro-
tein (p<0.01) expression of D2 receptors in comparison with
the morphine-sensitized group, see Fig. 3.
In the hippocampus, there were no significant alterations in
mRNA nor in protein expression of D2 receptors between the
morphine group and the saline group, while D2 receptor ex-
pression was significantly increased in the morphine-
sensitized group (p<0.05 and p<0.01 appropriately), com-
pared to the saline group. Significant differences were ob-
served between the morphine group and the morphine-
sensitized group (p<0.05). Both CPA and CGS 21680 signif-
icantly decreased mRNA (p<0.05 and p<0.001, appropriate-
ly) and protein (p<0.05 and p<0.01 appropriately) expres-
sion of D2 receptors, in comparison with the morphine-
sensitized group, see Fig. 3.
In the prefrontal cortex, the expression of mRNA and pro-
tein of D2 receptors was significantly up-regulated in the mor-
phine group vs the saline group (p<0.05, p<0.01, respective-
ly), while there were not significant alterations between the
morphine-sensitized group and the saline group. D2 receptor
expression was significantly down-regulated in the morphine-
sensitized group, compared to the morphine group (p<0.01).
It was also demonstrated that adenosine agonist, CPA, up-
regulated mRNA (p<0.05) and protein (p<0.01) expression,
in comparison with the morphine-sensitized group. CGS
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21680 did not induce any alterations in expression of D2 re-
ceptors in this brain area. The acute dose of naloxone did not
induce any changes in D2 receptor expression in any of the
studied brain areas, see Fig. 3.
Immunohistochemical experiments
Influence of continuous and sporadic morphine treatment
on immunohistochemical changes in D1 receptor expression
levels in the rat hippocampus during naloxone-induced
withdrawal period. The role of adenosine A1 and A2A
agonists
The results of the immunohistochemical reactions showed
changes in the expression of D1 receptor in the morphine
group (see Fig. 4(F–J)) and in the morphine-sensitized group
(see Fig. 4(K–O)), in comparison with the saline group (see
Fig. 4(A–E)). The intensity of reaction and the number of
immunopositive cells in the morphine group and the
morphine-sensitized group were comparable.
In the saline group, D1 receptor positive reactions were
observed in cytoplasm and plasmalemma of all the neurons
in the pyramidal cell layer (PyrCL) of CA1, CA2, CA3 re-
gions (see Fig. 4(A–C); the black arrows) and all the neurons
in CA4 region (see Fig. 4(D); the black arrows). Almost all the
cells of the granular cell layer (GCL) (see Fig. 4(E); the black
arrows) and a few larger cells in the polymorphic cell layer
(PCL) (see Fig. 4(E); the blue arrows) in the gyrus dentate
exhibited cytoplasmic reaction results.
In themorphine group, the cells ofCA1–CA4 regions showed
plasmalemmal/cytoplasmic receptor expression (see Fig. 4(F–I);
the black arrows), whereas only some of the cells in GCL of
gyrus dentate revealed an immunopositive reaction in cytoplasm
and plasmalemma (see Fig. 4(J); the black arrows).
Very intensive plasmalemmal/cytoplasmic receptor expres-
sion, stronger than in the saline and in the morphine group,
was observed in all the neurons of CA1 and CA2 regions of
PyrCL in the morphine-sensitized group (see Fig. 4(K, L); the
black arrows). Plasmalemmal/cytoplasmic receptor expression,
more intensive than in the saline group, but comparable to that
in the morphine group, was also shown in the neurons of CA3
regions of PyrCL (see Fig. 4(M); the black arrows) and CA4 (see
Fig. 4(N); the black arrows). In the gyrus dentate, plasmalemmal/
cytoplasmic immunoexpression of D1 receptor, significantly
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Fig. 2 Representative western blots and densitometric analysis of protein
(normalized to β-actin) (a) and densitometric analysis mRNA levels of
D1 receptor (b) in brain of continuously and sporadically treated with
morphine (mph) rats. The role of adenosine A1 and A2A agonists. The
results are expressed as means ± SD from different areas of three to four
rat brains. *p< 0.05, **p < 0.01 vs saline group; ^p< 0.05, ^^p < 0.01 vs
mph group; #p< 0.05 vs mph-sensitized group (Mann–Whitney test)
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lower than in cornu ammonis was observed in all the cells of
GCL (see Fig. 4(O); the black arrows) and in the larger cells in
PCL (see Fig. 4(O); the blue arrows). The intensity of reaction in
gyrus dentate of the morphine-sensitized group was stronger in
comparison to gyrus dentate of the saline group and comparable
to that in the morphine group.
Regarding the hippocampus, the number of positive cells
and the intensity of reaction in PyrCL of the CA1, CA2, and
CA3 region (see Fig. 4(P–S); the black arrows), observed in
the CPA in morphine-sensitized group, were high and compa-
rable with the corresponding values in the morphine-
sensitized group. In the CA4 region, a lower expression (see
Fig. 4(T); the black arrows) was evident, in comparison to the
receptor expression in the morphine-sensitized group. An
immunoexpression of D1 receptor, significantly stronger than
that in the morphine-sensitized group was noticed in GCL of
the gyrus dentate (see Fig. 4(U)).
In the CGS in morphine-sensitized group, cytoplasm and
plasmalemma of pyramidal cells of CA1, CA2, CA3 and cells
of CA4 were immunopositive but the intensity of reaction was
comparable to that in the morphine-sensitized group only in
CA1 regions (see Fig. 4(V); the black arrows) .
Immunoexpression in the neurons of CA2, CA3, and CA4
(see Fig. 4(W–Y); the black arrows) was noticeably weaker
than that in the morphine-sensitized group. Slightly lower
immunoexpression was also observed in the GCL of gyrus
dentate (see Fig. 4(Z); the black arrows) in comparison to
receptor expression in the morphine-sensitized group.
Influence of continuous and sporadic morphine treatment
on immunohistochemical changes in D2 receptor expression
in the rat hippocampus during naloxone-induced withdrawal
period. The role of adenosine A1 and A2A agonists
In the saline group, explicit D2 receptor immunoexpression
was demonstrated in the hippocampus. The pyramidal cells of
CA1–CA3 regions (see Fig. 5(A–C); the black arrows) and
the neurons of CA4 region (see Fig. 5(D), the black arrows)
showed receptor expression in plasmalemma and cytoplasm.
In the gyrus dentate, the expression of D2 receptor was also
observed in cellular plasmalemma and cytoplasm of the GCL
(see Fig. 5(E); the black arrows).
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Fig. 3 Representative western blots and densitometric analysis of protein
(normalized to β-actin) (a) and densitometric analysis mRNA levels of
D2 receptor (b) in brain of continuously and sporadically treated with
morphine (mph) rats. The role of adenosine A1 and A2A agonists. The
results are expressed as means ± SD from different areas of three to four
rat brains. *p < 0.05, **p< 0.01, ***p< 0.001 vs saline group; ^p < 0.05,
^^p < 0.01 vs mph group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs mph-
sensitized group (Mann–Whitney test)
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In the morphine group, cytoplasm and plasmalemma of all
the neurons in PyrCL of CA1, CA2, CA3 (see Fig. 5(F–H);
the black arrows) and the cells of CA4 (see Fig. 5(I); the black
arrows) were immunopositive but the intensity of reaction was
insensibly weaker than that in the saline group. In the gyrus
dentate (see Fig. 5(J); the black arrows), the number of D2
receptor positive cells and the intensity of reaction were com-
parable with receptor expression in the saline group.
Very intensive D2 receptor expression was indicated in the
cytoplasm and plasmalemma of all the neurons of CA1, CA2,
and CA3 regions of PyrCL (see Fig. 5(K–M); the black ar-
rows) and in CA4 region (see Fig. 5(N); the black arrows) in
the morphine-sensitized rats. The intensity of reaction in all
the parts of cornu ammonis was stronger than that in the saline
and morphine group. In the gyrus dentate, the plasmalemmal/
cytoplasmic immunoexpression of D2 receptor, significantly
lower than that in cornu ammonis, was observed in all the cells
of the GCL (see Fig. 5(O); the black arrows). The intensity of
reaction in gyrus dentate in the morphine-sensitized group
was comparable with reaction in gyrus dentate of the saline
and the morphine group.
In the hippocampus of the CPA in morphine-sensitized
group, D2 receptor expression, significantly lower than that
in the morphine-sensitized group, was evident in all the neu-
rons of CA1–CA4 regions (see Fig. 5(P–T); the black arrows).
Lower immunoexpression and a few immunonegative cells
were also observed in GCL of gyrus dentate (see Fig. 4(U);
the black arrows), in comparison to receptor expression in the
morphine-sensitized group.
The immunoexpression of D2 receptor within the hippocam-
pus in CGS in the morphine-sensitized group of rats is shown in
Fig. 5(V–Z). The neurons of PyrCL in CA1–CA3 regions and
neurons of CA4 region showed plasmalemmal/cytoplasmic D2
receptor immunoexpression (see Fig. 5(V–Y); the black arrows),
but the number of immunopositive cells was much lower than
that in the morphine-sensitized group. Significantly lower
immunoexpression of D2 receptor was noticed in the GCL of
gyrus dentate (see Fig. 5(O)). Only a small number of granular
cells showed low cytoplasmic reaction results.
Discussion
In the presented study, the effect of continuous (one withdraw-
al period) and sporadic (repeated withdrawal period) mor-
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Fig. 4 Immunolocalization of D1 receptor in hippocampus of rats during
withdrawal period induced by naloxone in: saline group (A–E); morphine
group (mph) (F–J); morphine-sensitized group (mph sensitization) (K–
O); CPA in mph-sensitized group (P–U); and CGS in mph-sensitized
group (V–Z); objective magnification ×40. (CA1–CA4) area of (CA)
cornu ammonis; (GD) gyrus dentate; (PyrCL) pyramidal cell layer;
(GCL) granular cell layer; (PCL) polymorphic cell layer; (MCL)
molecular cell layer
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withdrawal signs was examined. Although, various morphine
withdrawal signs were observed in studied animals, such as
wet dog shakes, paw tremors, or diarrhea, the number of
jumpings was chosen for analysis of behavioral changes, as
the most prominent morphine withdrawal symptom. In our
study, a continuous treatment with increasing doses of mor-
phine produced the expected state of dependence in rats. The
most important effect, observed in the presented experiments,
was such that a sporadic treatment with morphine (repeated
withdrawal signs) produced a significantly higher number of
jumpings in comparison with the signs which were observed
in continuously morphine-treated rats. It confirmed the as-
sumption of our investigation that previous experiences of
opioid withdrawal intensified subsequent withdrawal signs.
This phenomenon is referred to as the sensitization to with-
drawal signs. Furthermore, we indicated that the administra-
tion of selective adenosine A1 or A2A receptor agonists dur-
ing particular withdrawal episodes significantly reduced the
intensity of subsequent morphine withdrawals. Thus, in the
presented study, the important role of the adenosinergic sys-
tem in suppression of morphine sensitization was evidenced.
In these experiments, naloxone, which is commonly used
(Diaz et al. 2003; Done et al. 1992) to assess opioid
withdrawal signs, was used in dose of 2.0 mg/kg. That dose
was not able to induce any withdrawal signs in the saline and
did not influence the concentration of all neurotransmitters’
metabolites, either. Therefore, the obtained results in mor-
phine group and morphine-sensitized group are discussed in
comparison with those obtained in saline group.
In order to search for the DAergic mechanisms, underlying
the sensitization to morphine withdrawal in examined ani-
mals, neurochemical and molecular experiments were carried
out in the different brain structures: the striatum, the hippo-
campus, and the prefrontal cortex.
In neurochemical study, in the striatum, a cessation of mor-
phine administration in the morphine group induced a signif-
icant reduction of DA level, in comparison with the saline
group. That effect was in accordance with other reports, de-
scribing studies on the neurochemical effect of naloxone-
precipitated withdrawal period (Diaz et al. 2003; Tokuyama
et al. 1996). In morphine group, there was also a trend for
increased level of final metabolite—HVA and a statistically
significant increase in HVA/DA ratio. Lower concentration of
DA and increase in HVA/DA ratio suggest that chronic ad-
ministration of morphine may accelerate DA catabolism in the
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Fig. 5 Immunolocalization of D2 receptor in hippocampus of rats during
withdrawal period induced by naloxone in: saline group (A–E); morphine
group (mph) (F–J); morphine-sensitized group (mph sensitization) (K–
O); CPA in mph-sensitized group (P–U); and CGS in mph-sensitized
group (V–Z); objective magnification ×40. (CA1–CA4) area of (CA)
cornu ammonis; (GD) gyrus dentate; (PyrCL) pyramidal cell layer;
(GCL) granular cell layer; (PCL) polymorphic cell layer; (MCL)
molecular cell layer
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concentration of DA and its metabolites in the morphine-
sensitized rats which could be connected with repeated
withdrawal-induced adaptive changes within DAergic system.
Some experiments document that even single dose of mor-
phine induces long-lasting adaptation in mesolimbic system
(Marinho et al. 2015; Valjent et al. 2010; Vanderschuren et al.
2001). Moreover, Nestby et al. (1995) observed long-term
desensitization of D2 receptors in the rat striatum after cessa-
tion of intermittent administration of morphine. In our molec-
ular study, the decrease in D1, but not D2, receptor expression
was observed in the morphine group, while stronger reduction
in D1 and also D2 receptor expression was seen in the
morphine-sensitized group. Le Marec et al. (2001) also
showed in the striatum a higher density of D2 receptor in the
mice, chronically treated with morphine, and lower D2 densi-
ty in the sporadically treated group. Briefly, in the striatum,
one episode of morphine withdrawal (morphine group) leads
to alterations in the activity of DA neurons. They are associ-
ated with the reduction of DA concentration (induced by the
intensification of DA catabolism) and the decrease in D1 re-
ceptor density. While repeated morphine withdrawals
(morphine-sensitized group) induce also some adaptive
changes—a strong reduction of D1 and D2 receptors, but do-
pamine metabolism is not expressed. It seems that these dif-
ferences might be responsible for the higher expression of
morphine withdrawal signs in sensitized rats.
In the hippocampus of studied rats, marked neurochemical
differences in DA and its metabolites were observed. There
were no changes in the concentration of DA or its metabolites
(except for 3-MT) in the morphine group that was conform-
able with literature data (Diaz et al. 2003) but there was a
significant decrease in the concentration of DA, DOPAC and
final metabolite—HVA in the morphine-sensitized group.
Because HVA/DA ratio was unchanged, it can be concluded
that sporadic morphine administration did not influence an
enzyme level involved in DAmetabolism, and, lower concen-
tration of DOPAC and HVAwas caused by reduced DA level
in hippocampal neurons. Apart from, in the hippocampus, the
concentration of another DAmetabolite, 3-MT, and 3-MT/DA
ratio were significantly elevated, both in the morphine group
and the morphine-sensitized group. The lack of difference
between these groups seems to have no significance on the
expression of behavioral sensitization in studied rats. This
marked increase in 3-MT level may be explained by
morphine-evoked induction of some enzymes, taking part in
DAmetabolism. Similar increase in 3-MT level was observed
by other authors (Honkanen et al. 1994; Sotnikova et al. 2010)
and it may be an important antioxidant defense mechanisms
(Miller et al. 1996). Moreover, in molecular study, in the hip-
pocampus, no alterations were found in mRNA and protein
expression levels of D1 and D2 receptors in the morphine
group, while in the morphine-sensitized group, the expression
of these receptors was significantly higher. We found
immunoexpression of D1 and D2 receptors in the cells of
CA1–CA4 regions of cornu ammonis and in the GCL of gyrus
dentate in the morphine group. In the morphine-sensitized
group, more intensive immunoexpression of D1 receptor
was indicated, especially in the neurons of CA1 and CA2
regions of PyrCL of cornu ammonis, whereas the intensity
of D2 receptor immunoexpression was stronger than that in
the saline and in the morphine group in all the parts of cornu
ammonis. Thus, it seems that higher expression of D1 and D2
receptors in the hippocampus might have been correlated with
the reduction of DA and its metabolites (DOPAC and HVA)
concentration in that area and might have been responsible for
the expression of behavioral sensitization in studied rats.
In the rat prefrontal cortex, DA level in the morphine group
was increased in comparison with those in the saline group,
which was in accordance with literature data (Bassareo et al.
1995; Rossetti et al. 1993). In this group there was a tendency
toward to reduction level of a final metabolite—HVA and a
statistically significant decrease in HVA/DA ratio, indicating
that chronic administration of morphine may inhibit DA ca-
tabolism in the prefrontal cortex. However, in the morphine-
sensitized group, the DA level and the concentration of DA
metabolites (DOPAC, 3-MT, and HVA) were markedly poten-
tiated in comparison with the saline group. The HVA/DA ratio
was also significantly increased showing that repeated mor-
phine withdrawals may stimulate the enzymes involved in DA
metabolism. In the molecular study, we demonstrated higher
expression of protein and mRNA of D1 and D2 receptors in
the morphine group, and those expressions were not noticed in
the morphine-sensitized group. Thus, the lower expression of
DA receptors in the prefrontal cortex of sensitized rats was
correlated with the high levels of DA and its metabolites in
that brain structure.
All above discussed results showed substantial differences
between morphine group and morphine-sensitized group in
the striatum, the hippocampus and the prefrontal cortex, which
supports the significance of these brain areas in the expression
of morphine sensitization to withdrawal signs.
Regarding behavioral experiments, we also demonstrated
that both selective adenosine receptor agonists (CPA and CGS
21680) were able to attenuate sensitization to morphine with-
drawal signs in studied rats. In neurochemical study, following
the administration of CPA or CGS 21680 in the striatum, no
alterations were observed in the concentration of either DA or
its metabolites in comparison with the morphine-sensitized
group. In molecular study, in the striatum, both CPA and
CGS 21680 did not induce any changes in D1 receptor ex-
pression, but CPA produced a significant increase in D2 re-
ceptor expression in the CPA in morphine-sensitized rats, in
comparison with the morphine-sensitized group. Thus, CPA
restored the density of D2 receptor to control level which may
be important for lower expression of withdrawal signs in sen-
sitized rats.
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In the hippocampus, only 3-MT level was significantly
elevated by CPA and CGS 21680 in comparison with the
morphine-sensitized group. This increase might have been
caused by morphine-evoked interactions between adenosine
receptors and other receptors (e.g., DA receptors). Taking into
account that 3-MT is involved in antioxidant defense mecha-
nisms (Miller et al. 1996), and adenosine acts as endogenous
neuroprotective agent (Melani et al. 2014), it can be supposed
that observed in the hippocampus significant increase in 3-MT
level induced by CPA and CGS 21680 may be an interesting
phenomenon needed further studies. In the hippocampus, both
CPA and CGS 21680 significantly decreased the expression of
D1 and D2 receptors in the CPA and CGS 21680 in morphine-
sensitized group, restoring mainly D1, but also D2, receptor
levels, to the control density. It may be supposed that some
connections between high 3-MT level and adenosine recep-
tors may be involved in these effects, however it requires
further studies. Immunohistochemical analysis of the hippo-
campus revealed, for the first t ime, that reduced
immunoexpression of D1 receptor after the administration of
CGS 21680 was especially related to the neurons of CA2,
CA3, and CA4 regions of cornu ammonis, while after the
administration of CPA or CGS 21680, a significantly lower
immunoexpression of D2 receptor was observed in the neu-
rons of CA1–CA4 regions of cornu ammonis and in the neu-
rons of the GCL of gyrus dentate.
In the prefrontal cortex, only 3-MT level was significantly
elevated by CPA in comparison with the morphine-sensitized
group. CPA also significantly increased expression of D1 and
D2 receptor (the expression of mRNA of D1 receptors was
close to statistical significance) reversing the changes induced
by sporadic morphine administration. The distribution of A2A
receptors in prefrontal cortex is poor (Ferré et al. 1997) and
this may be the reason for the lack of effect CGS 21680 in that
structure.
Thus, in this part of the study, we demonstrated that both
selective adenosine receptor ligands were able to attenuate the
morphine sensitization to withdrawal signs by influence on
the activity of D1 and D2 receptors in three examined brain
areas. It should be noted that both ligands were administered
during three withdrawal periods, but not in the experimental
day, which indicate that they are able to produced long-term
effects on the sensitization to morphine withdrawal signs.
Taken together, in the present manuscript, we demonstrate
that intermittent morphine administration intensifies the sub-
sequent morphine withdrawal signs (i.e., sensitization to mor-
phine withdrawal signs) and that selective adenosine receptor
agonists are able to attenuate this phenomenon in rats. It seems
that this model of the sensitization reflects the schedule of
morphine administration in addictive humans, taking into ac-
count the impossibility to take a drug. Additionally, we show
the significant alterations within DAergic system at the neu-
rochemical and the molecular level which are involved in
sensitization to morphine withdrawal. Firstly, we have dem-
onstrated changes which are developed during repeated with-
drawals: (1) in the striatum, the repeated withdrawals induce
strong reduction of DA receptor density, without effect on DA
level; (2) in the hippocampus, the significant attenuation of
DA concentration and high expression of DA receptor; (3) in
the prefrontal cortex, significant increase in DA level without
the effect on DA receptor expression. Secondly; we have
shown changes in DAergic system which occur after stimula-
tion of adenosine receptors: (1) stimulation of adenosine re-
ceptors by CPA or CGS 21680 does not influence on DA and
its metabolites concentration in all studied brain areas; (2) in
the striatum, the administration of CPA, but not CGS 21680,
restore the density of D2 receptor to control level; (3) in the
hippocampus, both adenosine ligands reduce the expression
of D1 and D2 receptors recovering their level to control
values; (4) in the prefrontal cortex, CPA, but not CGS
21680, significantly increased the expression of D1 and D2
receptor density, reversing the changes induced by sporadic
morphine administration.
The present experiments have shown how complex and
multi-level changes occur after morphine administration, thus
posing a challenge to have the alterations reversed with a
perspective to develop an effective therapy for morphine-
addicted patients.
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